metaPreg - Misoprostol during pregnancy

Misoprostol

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Congenital malformations
Major congenital malformations	2.86 [1.44, 5.65]	0%	3 studies	36	388	not evaluable	ROB
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.64 [1.03, 6.76]	-	1 study	86	118	not evaluable	ROB
Nervous system anomalies	4.23 [1.47, 12.16]	-	1 study	34	145	not evaluable	ROB
Limb reduction defects (LRD)	15.12 [5.53, 41.34]	0%	2 studies	61	47	not evaluable	ROB
Moebius syndrome	32.19 [10.54, 98.31]	0%	2 studies	125	74	not evaluable	ROB
Oro-facial clefts	5.74 [1.34, 24.59]	-	1 study	34	52	not evaluable	ROB
Abdominal wall defects	6.36 [2.38, 16.96]	-	1 study	34	23	not evaluable	ROB
Vascular disruption anomalie	22.00 [6.59, 73.42]	-	1 study	93	44	not evaluable	ROB
5 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Preterm (< 37 weeks)	3.51 [1.38, 8.91]	-	1 study	20	145	not evaluable	ROB
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Early intrauterine death (< 22 weeks)	2.16 [1.40, 3.34]	36%	2 studies	36	296	not evaluable	ROB
Intrauterine deaths (as a whole or unspecified)	2.27 [1.30, 3.97]	-	1 study	46	94	not evaluable	ROB
Elective/induced termination of pregnancy	5.33 [2.93, 9.71]	-	1 study	74	236	not evaluable	ROB
2 non statistically significant endpoints reported in only one study